Jing Chen
About Jing Chen
Jing Chen is a Principal Scientist at Bristol Myers Squibb with extensive experience in GPCR pharmacology and immune/cancer cell trafficking.
Company
Jing Chen currently holds the position of Principal Scientist at Bristol Myers Squibb. Chen has an extensive history with the company, previously serving in roles such as Senior Research Scientist/Project Manager and Research Scientist. Chen's work at Bristol Myers Squibb has spanned various aspects of drug discovery and development, including immunology, oncology, and cardiovascular research.
Title
Jing Chen is a Principal Scientist at Bristol Myers Squibb. In this role, Chen oversees significant scientific research and development projects, contributing to various aspects of drug discovery and safety evaluations. With a robust background in project management and regulatory affairs, Chen plays a critical role in ensuring the scientific rigor and regulatory compliance of the company's research initiatives.
Education and Expertise
Jing Chen holds a Master's degree in Cellular and Molecular Biology from New York University. Chen's expertise encompasses GPCR pharmacology, immune and cancer cell trafficking/invasion, and multiple disease areas including immunology, immuno-oncology, oncology, cardiovascular, fibrosis, metabolic disease, infectious diseases, and CNS drug discovery. Chen is also skilled in platforms such as ELISA, Kinase, GPCR, HCS, HTS flow cytometry, and more.
Background
Jing Chen has a long history of service at Bristol Myers Squibb, where Chen started as a Research Scientist from 2004 to 2009. This was followed by a role as a Senior Research Scientist/Project Manager from 2009 to 2017. In these positions, Chen contributed to over 35 programs and authored analytical methods for numerous IND filings. With over 8 years of experience in project management for in vitro drug safety panels, Chen has substantial expertise in toxicology and safety data authoring.
Regulatory and Budget Management
Jing Chen holds a certificate in 'Clinical Development and Regulatory Affairs,' bringing comprehensive knowledge of clinical development processes including GLP, GCP, and GMP. Chen has thorough knowledge of the FD&C Act, 21 CFR, and ICH Guidelines, along with a solid understanding of clinical development and FDA regulations for IND and NDA. Additionally, Chen is proficient in internal budget management and external budget negotiation for instrumentation purchase and services.